Item Posts Archive - Page 50 of 1770 - Medivizor
Navigation Menu

Evaluating the effectiveness and safety of continuous subcutaneous night-time only apomorphine for the treatment of insomnia in patients with Parkinson’s disease.

Evaluating the effectiveness and safety of continuous subcutaneous night-time only apomorphine for the treatment of insomnia in patients with Parkinson’s disease.

Posted by on Sep 18, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of continuous subcutaneous night-time only apomorphine (Apokyn) infusion for the treatment of insomnia in patients with Parkinson’s disease (PD). The data showed that continuous subcutaneous night-time only apomorphine was effective in improving sleep disturbances in patients with...

Read More

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Posted by on Sep 18, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...

Read More

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Read More

Evaluating the short-term functional outcomes and safety of holmium and thulium fiber laser enucleation of the prostate treatment for patients with benign prostatic hyperplasia.

Evaluating the short-term functional outcomes and safety of holmium and thulium fiber laser enucleation of the prostate treatment for patients with benign prostatic hyperplasia.

Posted by on Sep 18, 2022 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study evaluated the short-term functional outcomes and safety of holmium (HoLEP) and thulium fiber laser enucleation of the prostate (ThuFLEP) treatment for patients with benign prostatic hyperplasia (BPH). The data showed that both HoLEP and ThuFLEP surgeries are similar in terms of functional outcomes and safety in these patients....

Read More

Evaluating the renin-angiotensin-aldosterone system inhibitors effects on mortality and disease severity in patients with COVID-19

Evaluating the renin-angiotensin-aldosterone system inhibitors effects on mortality and disease severity in patients with COVID-19

Posted by on Sep 18, 2022 in Hypertension | 0 comments

In a nutshell This review analyzed the effect of renin-angiotensin-aldosterone system (RAAS) inhibitors including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on patient prognosis for COVID-19. The data suggested that there is no association between the use of ACEIs/ARBs and the risk of mortality and...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor